Date: November 04, 2026

To,
The Manager- Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, Block-G,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051

SYMBOL: REMUS

Dear Sir/Madam,

Sub.: Investor Presentation for H1-FY27

In terms of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and our intimation dated October 28, 2026, regarding the Earnings Conference Call, we enclose herewith the Investor Presentation for H1-FY27.

The aforesaid information is also being hosted on the Company's website at www.remuspharma.com.

You are requested to take the same on record.

Thanking you.

For, Remus Pharmaceuticals Limited

DEVAL BAKULKUMAR PATEL

Digitally signed by DEVAL BAKULKUMAR PATEL
Date: 2026.11.04 12:02:00 +05'30'

Deval Patel
Company Secretary and Compliance Officer
ICSI Membership No.: A60090

Encl: As Above

Remus®
Dedicated to Global Healthcare




Investor Presentation

November 2026

www.remuspharma.com

Snapshot



First-to-market products in **niche** therapies.



FY26 Return Ratios
RoE*: **13.16%**
RoCE*: **14.13%**
Net Debt to Equity: **0.03**



955+ registered products, **275+** products commercialized, **2,100+** SKU's across **diverse therapeutic** segments



Over **150+** distributors globally



Strong last-mile reach through **D2C + pharmacy channels** with high end product therapies



825+ dossier ready-to-file for various geographies



Asset-light model with scalable growth

*ROE & ROCE, Calculated on increased Capital base due to IND AS impact

Contents

1 Company Overview

2 Business Overview

3 Strategic Overview

4 Industry Overview

5 Financial Overview


Remus
Dedicated to Global Healthcare



Company Overview

Company Overview

- Remus Pharmaceuticals Limited, established in 2015, is one of the fastest growing pharmaceutical companies.
- Remus specializes in branding, marketing, and distribution of complex specialty and niche off patent formulations in various countries.
- The company has a diversified portfolio of 955+ approved products, 560+ MOH submitted/under evaluation products as on H1 FY27, and 2400+ dossier registrations in major geographies.
- The product portfolio includes formulations across major therapeutic segments including oncology, cardiology, dermatology, diabetes etc.
- Remus works on an asset light model and a quick go-to market strategy of identifying off patent drugs with strong market potentials and undergoing R&D, dossier filings in relevant countries.
- Remus identifies and partners with CDMO and CMO sites that hold the appropriate accreditations as required by each country. We collaborate with over 27 global manufacturing partners.
- It has a strong marketing and distribution presence through local distributors in 40+ semi regulated markets of Latin America, Southeast Asia, Middle East, CIS and Africa, and also direct presence through established subsidiaries in Bolivia and Guatemala.
- The company is also expanding market reach through channel partners for large government and institutional tenders.
- Remus made a foray into the U.S. through the acquisition of Espee Global Holdings LLC in 2024, which operates as one of the largest distributor of Reference Listed Drugs (RLDs) and leader in sourcing and supplying hard-to-access REMS, specialty, orphan, and biosimilar drugs, serving 300+ customers across 30+ countries through an FDA-approved facility.



Key Milestones

2015 — Business Consolidation

- Initiated **exports** of finished formulations.
- Launched **global marketing** for Remus in semi-regulated & emerging markets.

2017-2019 — Collaboration & Partnership Building

- Forged partnerships with leading multinational pharmaceutical companies.
- Enhanced global **brand equity** and expanded distribution capabilities.
- Focused on compliance, **dossier development**, and registration in high-potential geographies.

2022 — Strategic Market Presence

- Initiated presence in key **international markets** with focused product launches.
- Created a foundation for sustainable market penetration and regulatory approvals.
- Strengthened internal capabilities for exports.

2023 — Subsidiary Expansion

- Incorporated subsidiaries in **Bolivia** and **Guatemala** to localize market access.

2024 — Strengthening LATAM Presence and Exploring New Markets

- **Acquired Espee USA**
- **LATAM Expansion**: Deepened presence via incorporation in new countries and long-term alliances with local distributors.
- **Created Relius** brand for advance market development, specialty product launches, and last-mile distribution
- **Contractual partnerships** with sub-distributors and **major pharmacy chains** to optimize market reach and ensure sustainable growth in semi-regulated markets.

2025-2026 & Beyond — Expansion & R&D Focus

- Targeting entry into 5+ new territories including **Eastern Europe, Africa,** and **ASEAN** regions.
- Participation in **Bolivia's** national tenders with a diversified portfolio of 10+ products.
- **R&D**-driven portfolio expansion.
- Strategic launch of Central Nervous System portfolio through **D2C** channel with 6 specialized molecules.

Experienced Board of Directors



Mr. Arpit Shah
Managing Director

Mr. Arpit Shah , an Engineer from Gujarat University, instrumental to the business growth, handles business developments, alliance management, strategic decisions and portfolio expansion. He has worked for a large US based conglomerate.



Mr. Swapnil Shah
Chairman & Non- Executive, Non- Independent Director

Mr. Swapnil Shah holds a master's degree in Business Administration with a specialization in Finance & International Business from Hofstra University, New York, and a bachelor's degree in Chemical Engineering from Nirma University. He is involved in the business development and corporate strategy of the company. Prior to Remus, he worked as a Strategist in a NASDAQ listed Fintech company.



Ms. Roma Shah
Whole-time Director

Ms. Roma Shah holds a master's degree in Pharmaceutical Manufacturing from the USA and a bachelor's degree in Pharmacy from Gujarat University. She has been a strong pillar of the organization in the field of Regulatory, R&D, and strategic business support & management. She specializes in all critical technical aspects of the company.



Ms. Anar Shah
Non- Executive, Non- Independent Director

She is a silver medalist in Master of Business Administration with a specialization in Family Business & Entrepreneurship from Nirma University. She is a dentist by education and holds a bachelor's degree in Dental Surgery from BVDU Medical College. She is responsible for activities related to human resource development.



Mr. Vishrut Pathak
Non-Executive Independent Director

He holds a master's degree in Business Administration in International Finance from St. John's University and a PGD degree in Financial Statement Analysis from New York University. With over 20 years of rich experience in Investment Management and Corporate Finance, he mentors at EDII under the CrAdLE platform.



Ms. Sanjana Shah
Non-Executive Independent Director

Ms. Sanjana Shah, Non-Executive Independent Director of the company. She is a certified Chartered Accountant and holds a bachelor's degree in Law. In her 12 years of career in the field of Accounts and Financial Management, she has gained expertise in Mergers and Acquisitions, Financial Analysis, Credit Rating, and part of IR team.



Mr. Balwant Purohit
Non-Executive Independent Director


Mr. Balwant Purohit is a Non-Executive Independent Director of the company. He has extensive experience in hospitality management. His business caters to more than 600 clients annually across India under various catering and corporate events. He is result-oriented and resourceful with a proven ability to develop and strengthen management team to maximize efficiency.



Mr. Ashutosh Naginbhai Valani
Non-Executive Independent Director

Mr. Ashutosh Naginbhai Valani is a Non-Executive Independent Director of the company. He has around 18 years of experience across e-commerce, FMCG and Beauty & Personal Care sectors. He is the Co-founder & Director of Renee Cosmetics and previously founded Beardo and Villain. He is also an angel investor and has been recognised in Forbes 30 Under 30 and Fortune 40 Under 40.

Strong Global Presence



Total 2,443+

Commonwealth of Independent States - 83

54 Under Process

29 Registered

CIS & Eastern Europe
- Azerbaijan
- Uzbekistan
- Georgia
- Kosovo

South East Asia - 412

336 Under Process

76 Registered

Asia & South-East Asia
- Bhutan
- Malaysia
- Myanmar
- Philippines
- Thailand
- Vietnam

Latin America – 1,805

936 Under Process

869 Registered

South, Central America & Caribbean Islands
- Cuba
- Dominican Republic
- Jamaica
- Trinidad & Tobago
- Costa Rica
- El Salvador
- Guatemala
- Honduras
- Nicaragua
- Panama
- Bolivia
- Chile
- Ecuador
- Mexico
- Peru
- Suriname
- Venezuela
- Colombia
- Guyana
- Haiti

Africa - 103

88 Under Process

15 Registered

Africa
- Ivory Coast
- Kenya
- Algeria
- Madagascar
- Mauritius
- Namibia
- Nigeria
- Rwanda
- Tanzania
- Zambia

Middle East - 40

34 Under Process

6 Registered

Middle East
- Kuwait
- Lebanon
- Saudi Arabia

Remus
Dedicated to Global Healthcare



Business Overview

Business Value Chain



Market Research	Product Indentification	Product Registration	Procurement	Manufacturing	Export	Marketing & Distribution
• Track global therapy trends • Monitor patent expiries	• Focus on high-margin, off patent molecules • Align with market gaps and regulatory fit	• Prepare dossiers through in-house regulatory team • File across multiple countries for faster approvals	• Global standard packing inputs	• We outsource ready-to-market products from manufacturers who have already completed development. • Manufacturing partners approved by global regulators, ensuring export market compliance	• B2B Export Supplying finished products to global distributors under their brands and product registrations • D2C Export Direct exports to our Relius subsidiaries for importation, sales, marketing and to create own brand presence	• Dedicated sales & distribution teams ensuring smooth movement of products from warehouses to patients • Focused on building strong brand recall and establishing category leadership across key export markets

Product Registration & Regulatory Roadmap

Step 01	Step 02	Step 03	Step 04	Step 05	Step 06	Step 07
Market & Product Identification	**Technical Feasibility & Partner Alignment**	**Formulation Development**	**Data Compilation for Dossier**	**Regulatory Review & Compliance Check**	**Submission to Health Authorities**	**Commercial Launch Readiness**
Assessment of demand, competitive landscape, and registration pathways in target countries. Product selection focuses on off-patent, high-margin formulations with strong market potential.	Tie-up with qualified third-party manufacturers (CMOs) for formulation development. Verification of manufacturing capabilities, stability data, and existing validations.	Customized formulation as per regulatory and climatic zone requirements. Includes pilot batch production, lab testing, and process validation as per WHO/ICH norms.	Preparation of Common Technical Document covering: Administrative /legal info - Quality-Non-clinical and clinical overviews Inclusion of analytical methods, stability data, packaging specs and bioequivalence references (if applicable).	In-house regulatory team ensures alignment with country-specific Ministry of Health norms. Gap analysis, technical justification drafting, and document standardization are performed.	Final dossier submitted to local regulatory agencies for marketing authorization. Remus manages queries, deficiency responses, and follow-ups until approval.	Upon approval, products are branded, packaged, and supplied via B2B, B2C, or institutional channels. Simultaneous filing in multiple geographies allows first-mover advantage

Regulatory QC/QA



Expert Regulatory Affairs Team

A highly skilled team of 30+ professionals, each specializing in key regions and complex products, including Oncology, Biosimilars, and Monoclonal Antibodies (MAB), Peptides.



Dossier Submission Excellence

Submitting 50+ dossiers monthly, with strong compliance to country-specific regulations.



Bioequivalence, Clinical, and Non-Clinical Research

Performing bioequivalence and clinical studies for compliance, and preparing non-clinical research to meet regulatory standards.



Dynamic & Adaptive Team

Dynamic and young team, technically skilled professionals and a business-focused group to stay closely aligned with market trends and demands.



Timely & Strategic Assessment

Conducting up-to-date studies to ensure products are market-ready and strategically aligned.



Quality Assurance & Control

Multi-step quality checks including IPQC, Batch Testing, Stability and Visual Inspections, Lab Testing, and Packaging Integrity to ensure safety and compliance.

B2B Business

Partner Driven Scalability

- End-to-end regulatory & commercial solutions for global partners
- Fast-track entry into **semi-regulated** & **emerging markets**
- In-house regulatory expertise ensuring swift market access
- Low R&D risk, faster commercialization timelines
- Strong scalability via partners' **marketing & distribution networks**
- Controlling high-quality dossiers, monetizable across markets
- **Low working capital**—no inventory or promotional spend
- Participating in **large government and institutional tenders**

Some of our niche and complex formulations



Amlodipine, Valsartan and Hydrochlorothiazide Tablets 5mg, 160mg, 12.5mg



Eltrombopag Tablets 25mg




Bempedoic Acid Tablets 180mg, 180+10mg



Palbociclib Capsules 125mg

Top Countries Growth



B2C Business

Brand-Led Profitability

- Operates under Relius brand via Bolivia & Guatemala subsidiaries
- Strong last-mile reach through **D2C + pharmacy channels**
- High safety & efficacy aligned with global standards
- Building brand equity via **trademark protection & market presence**
- Captures full value chain—**higher per-unit margins**
- Commands **premium pricing & differentiation** in commoditized markets

Some of our branded products



Sacubitril & Valsartan tablets 50, 100, 200 mg



Iopromide Injections 300, 370 mg I/ml



Sodium Valproate Tablets BP 500mg



Heparin Injection 25000IU



Carbidopa + Levopada Tablets 25 mg + 250 mg



Iron Sucrose Injection 20mg/ml



Dexketoprofen Injection 25 mg/ml



Lactulose Oral Solution 10 mg – 15ml



Rivaroxaban Tablets BP 10, 15, 20 mg



Cabergoline Tablets USP 0.5 mg



Fosfomycin Trometamol Powder - Sachet



Apixaban Tablets 2.5mg ,5mg

Integrated Product Snapshot

SKUs

Tablets
1227*

Ointments, Creams & Gels
69*

Injectables
692*

Inhalers/ Nebulizer
38*

Syrups & Oral Suspensions
117*

Capsules (Hard Gel & Soft Gel)
253*

Other Products
47*

Biosimilars

Oncology


Powder for Injections

Ophthalmic


Sachets

* Number of SKU's also Includes registered, filed and products under process of filing

Registered Products



Therapeutic-Wise Registrations (%)





Espee
Empowering Healthcare

One of the world's largest pharmaceutical finished formulations specialty distributors and clinical trial service provider

Remus
Dedicated to Global Healthcare

Among the world's largest RLD distributors – Extensive global network and sourcing capabilities with an expertise in sourcing and supplying hard-to-get REMS, specialty, orphan, and biosimilar drugs.

Advanced Supply Chain – Customized dashboards, trend analysis, and complete logistics support for global, compliant deliveries.

High-ROE business – Generates strong returns on equity by combining operational efficiency with disciplined capital allocation, translating into higher profitability for shareholders.

Diverse Client Base – Trusted partner to 300+ largest global pharmaceutical conglomerates, including top generic pharma companies, biopharma innovators, R&D organizations, CMOs, CROs, and government agencies.

Remus
Dedicated to Global Healthcare



Strategic Overview

Key Strengths

Future-Ready Portfolio


Comprehensive data on molecules going **off-patent up to 2038**

Brand Excellence

Registering and **trademarking** our own brands, building a regional presence

Swift Market Entry

Developing recently **off-patent products** for **First Mover Advantage**



Global Tie-ups

Strong strategies for **MABs, Biosimilars,** and **Niche Formulations** and **peptides**

Strong Global Footprint

Presence across various strategic **untapped** markets

Wide Product Portfolio

One of the largest portfolio of **900+** approved products and **850+** ready dossier for registration across major geographies

Regulatory Expertise

A robust regulatory affairs team ensures **compliance with evolving guidelines of 35+ ROW Markets , 7+ Semi Regulated and Regulated markets**

Supply Chain Agility

Robust sourcing network and flexible manufacturing partnerships enable rapid scale-up and reliable global deliveries.

Growth Strategies


- Building strong direct-to-consumer (D2C) and pharmacy networks
- 600+ B2C products in development, Targeting 200+ B2C launches and over 2,100 new product filings
- Training field force for ethical, doctor-driven promotion
- New market entries: Bosnia, Ethiopia, Algeria Kosovo, Mexico, Tanzania, etc.
- Increase presence in developed markets – organic and acquisition route
- Expand presence in semi-regulated and emerging markets by accelerating product registrations

Remus
Dedicated to Global Healthcare



Industry Overview

Global Pharmaceutical Market



The Global Pharmaceutical formulations market was valued at USD $1,511 Bn in FY2025, up from USD $1,289 Bn in FY2022.
It grew at a CAGR of approximately 5.4% between FY2022 and FY2025, driven by sustained demand in key therapy areas such as Oncology, Alimentary Tract & Metabolism, and Central Nervous System disorders. It is expected to grow with a steady CAGR of ~5.4% from FY2025 until FY2027 to reach USD $1673 Bn.


Global Pharmaceutical Market by Region (in USD Bn) :- Between 2010-2020, Asia has grown exponentially and is now the heart of the global pharma industry. It is driving innovation, growth, and future development within the pharma sector. Globally, China and Japan are the second and third largest pharmaceutical markets.

Source: IQVIA, Frost & Sullivan Research and Analysis

Global Demand Drivers

- Increase in ageing population
- Increasing prevalence of chronic diseases
- Strong growth of global generic market
- Expansion of health insurance coverage

Global Pharmaceutical Market Growth (in USD Bn)



Indian Export Market

India ranks 3rd globally in pharmaceutical production by volume, known for its generic medicines and low-cost vaccines.

Exports reach 200+ countries, with the US as the largest market.

In FY25, exports stood at INR 2.60 lakh crore (USD 30.47 billion); FY26 (Apr–Feb) exports at INR 2.66 lakh crore (USD 28.29 billion).


India contributes ~20% of global generic drug exports.

Emerging markets such as Latin America and ASEAN showing double-digit growth in FY25, adding depth to India's export base.

Pharma exports expected to grow 10x–15x, reaching USD 350 billion by 2047.



Major Export Destination in India's Pharma Export in FY26 (%)



Remus
Dedicated to Global Healthcare



H1-FY27


Performance Highlights

Half Yearly Financial Highlights


Remus
Dedicated to Global Healthcare

Consolidated


Operational Revenue (INR Mn.)



EBITDA (INR Mn.)




PAT (INR Mn.)




Standalone


Operational Revenue (INR Mn.)



EBITDA (INR Mn.)



PAT (INR Mn.)



Q2/H1-FY27 Operational Highlights

- Won tender of 24 products in Bolivia.
- In-licensed several new molecules for Mexico, Chile, Vietnam, and Peru, supported by bioequivalence (BE) studies, strengthening the anti-infective and anti-allergy portfolio.
- Peru: Got plant approved by Digemid. Currently filling 60+ products in Peru.
- Secured a direct government tender in Venezuela.
- Product Registration and Approval in Venezuela.
- Biological Products
- Got Approval of Semaglutide Tablets and Injections. Commercialization is planned soon.
- Executed supply orders for Rotigotine Patches in Venezuela and initiated filings in Venezuela and other markets, expanding the CNS portfolio. This is our second Patch launch in the market.
- In discussion to In-licensed several other Biosimilar products which will add to our portfolio.
- Received Trademarks and Brand Approvals of products in Dominican Republic. Planning the B2C launch of products soon.
- Introducing 5+ new brands to be marketed and sold in Guatemala under own label

Half Yearly Standalone Income Statement

PARTICULARS (INR Mn)	H1-FY27	H1-FY26	Y-O-Y	H2-FY26	H-O-H
Operational Revenue	**621**	**469**	**32.4%**	**471**	**31.8%**
Operating Expenses	404	321	*25.9%*	321	*25.9%*
EBITDA	**217**	**148**	**46.6%**	**150**	**44.7%**
EBITDA Margin (%)	***34.94%***	***31.56%***	***338 Bps***	***31.85%***	***309 Bps***
Depreciation and Amortisation	12	13	(7.7)%	15	(20.0)%
Finance costs	3	2	50.0%	4	(25.0)%
Other Income	45	28	60.7%	41	9.8%
PBT	**247**	**161**	**53.4%**	**172**	**43.6%**
Tax Expense	59	41	43.9%	45	31.1%
PAT	**188**	**120**	**56.7%**	**127**	**48.0%**
PAT Margin (%)	***30.27%***	***25.59%***	***468 Bps***	***26.96%***	***331 Bps***
Other Comprehensive Income	1,669	329	NA	271	NA
Total Comprehensive Income	**1,857**	**449**	**NA**	**398**	**NA**
Diluted EPS	15.96	10.21	*56.3%*	10.75	*48.5%*

Half Yearly Consolidated Income Statement

PARTICULARS (INR Mn.)	H1-FY27	H1-FY26	Y-O-Y	H2-FY26	H-O-H
Operational Revenue	**6,141**	**4,002**	**53.4%**	**4,534**	**35.4%**
Operating Expenses	5,842	3,733	*56.5%*	4,236	*37.9%*
EBITDA	**299**	**269**	**11.2%**	**298**	**0.3%**
EBITDA Margin (%)	***4.87%***	***6.72%***	***(185) Bps***	***6.57%***	***(170) Bps***
Depreciation and Amortisation	15	13	15.4%	15	NA
Finance costs	8	7	14.3%	8	NA
Other Income	42	30	40.0%	38	10.5%
PBT	**318**	**279**	**14.0%**	**313**	**1.6%**
Tax Expense	71	63	12.7%	67	6.0%
PAT	**247**	**216**	**14.4%**	**246**	**0.4%**
PAT Margin (%)	***4.02%***	***5.40%***	***(138) Bps***	***5.43%***	***(141) Bps***
PAT Attributable to Owners of the Holding Company	**218**	**175**	**24.6%**	**195**	**11.8%**
Other Comprehensive Income	1,653	338	NA	263	NA
Total Comprehensive Income	**1,900**	**554**	***NA***	**509**	***NA***
Diluted EPS	20.92	18.33	14.1%	20.86	0.3%



Historical Financials

Historical Consolidated Income Statement

PARTICULARS (INR Mn)	FY24	FY25	FY26	H1-FY27
Operational Revenue	**2,129**	**6,204**	**8,536**	**6,141**
Total Expenses	1,839	5,747	7,969	5,842
EBITDA	**290**	**457**	**567**	**299**
EBITDA Margins (%)	***13.62%***	***7.37%***	***6.64%***	***4.87%***
Depreciation and Amortisation	11	19	28	15
Finance costs	5	15	15	8
Other Income	28	50	68	42
PBT	**302**	**473**	**592**	**318**
Tax	59	89	130	71
PAT	**243**	**384**	**462**	**247**
PAT Margins (%)	***11.41%***	***6.19%***	***5.41%***	***4.02%***
Diluted EPS (INR)	21.48	32.61	39.19	20.92

Note: Financials for Subsidiaries set up/acquired during the relevant FY has been considered from the date of incorporation/date of acquisition, as applicable

Historical Consolidated Balance Sheet


ASSETS (INR Mn)	FY25	FY26	H1-FY27
Non-current assets			
a) Property, Plant & Equipment	49	57	147
b) Capital Work-In-Progess	-	83	-
c) Goodwill on Consolidation	87	87	87
d) Other Intangible Assets	-	-	3
e) Intangible Assets Under Development	1	2	1
f) Right to Use Assets	21	39	33
g) Financial Assets			
i) Non-Current Investments	1,861	2,570	4,570
ii) Long-term Loans and Advances	-	-	-
iii) Other Financial Assets	93	2	24
h) Deferred Tax Asset (net)	-	-	-
i) Other Non-current Asset	-	-	-
Total of Non-current assets	**2,112**	**2,840**	**4,865**
Current assets			
a) Inventories	516	721	745
b) Financial Assets			
i) Current Investments	-	175	266
ii) Trade Receivables	1,080	1,391	1,318
iii) Cash and Cash Equivalents	72	118	100
iv) Bank Balance other than above	9	11	7
v) Short-Term Loans And Advances	209	91	97
vi) Other Financial Assets	192	258	180
c) Current Tax Asset (net)	-	-	-
d) Other Current Assets	136	182	298
Total Current assets	**2,214**	**2,947**	**3,011**
Total Assets	**4,326**	**5,787**	**7,876**

EQUITY & LIABILITIES (INR Mn)	FY25	FY26	H1-FY27
Equity Share Capital	59	118	118
Reserve and Surplus	2,500	3,392	5,240
Total Equity	**2,559**	**3,510**	**5,358**
Non-Controlling Interest	**267**	**367**	**413**
Liabilities			
Non-current liabilities			
a) Financial Liabilities			
i) Long-Term Borrowings	33	57	58
ii) Lease Liabilities	16	30	29
b) Long -Term Provision	7	6	7
c) Deferred Tax Liabilities (Net)	229	325	606
d) Other Long-Term Liabilities	-	-	-
Total of Non-current liabilities	**285**	**418**	**700**
Current liabilities			
a) Financial Liabilities			
i) Short-Term Borrowings	175	174	162
ii) Lease Liabilities	5	10	6
iii) Trade Payables			
Total outstanding Dues for Creditors belongs to Micro & Small Enterprises	18	24	13
Total outstanding Dues for Creditors belongs other Micro & Small Enterprises	695	737	728
iv) Other Financial Liabilities	3	6	6
b) Other Current Liabilities	283	456	398
c) Short-Term Provision	8	19	20
d) Current Tax Liabilities (Net)	28	66	72
Total of Current liabilities	**1,215**	**1,492**	**1,405**
Total Liabilities	**1,500**	**1,910**	**2,105**
Total Equity & Liabilities	**4,326**	**5,787**	**7,876**


Note: Financials for Subsidiaries set up/acquired during the relevant FY has been considered from the date of incorporation/date of acquisition, as applicable

Standalone Financial Highlights


Revenue From Operation (INR Mn.)




EBITDA (INR Mn) & EBITDA Margins (%)




PAT (INR Mn) & PAT Margins (%)




Net Debt to Equity (X)



Trade Receivables Days




ROCE* (%) & ROE* (%)




*ROE & ROCE, Calculated on increased Capital base due to IND AS impact

Consolidated Financial Highlights


Revenue From Operation (INR Mn.)




EBITDA (INR Mn) & EBITDA Margins (%)




PAT (INR Mn) & PAT Margins (%)




Net Debt to Equity (X)



Working Capital Days




ROCE* (%) & ROE* (%)



*ROE & ROCE, Calculated on increased Capital base due to IND AS impact

Capital Market Data


1 Year Share Price Movement (Up to 30th September 2026)



Price Data (As on 30th September 2026)

Face value (INR)	10.0
Market Price (INR)	903.2
52 Week H/L (INR)	1,007.0 / 580.0
Market Cap (INR Mn.)	10,643.3
Equity Shares Outstanding (Mn.)	11.8
1 Year Avg. trading volume ('000)	6.7

Shareholding Pattern (As on 30th September 2026)



Disclaimer

Remus Pharmaceuticals Ltd. Disclaimer:

The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation should not be construed as legal, tax, investment or other advice. This presentation is confidential, being given solely for your information and for your use, and may not be copied, distributed or disseminated, directly or indirectly, in any manner. Furthermore, no person is authorized to give any information or make any representation which is not contained in, or is inconsistent with, this presentation. Any such extraneous or inconsistent information or representation, if given or made, should not be relied upon as having been authorized by or on behalf of the Company.

Certain statements in this presentation may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

For further details, please feel free to contact our Investor Relations Representatives:

VALOREM ADVISORS
"Your Partners in Value Creation"

Mr. Anuj Sonpal
Valorem Advisors
Tel: +91-22-35075100
Email: remus@valoremadvisors.com
To access the Investor Kit link and/or request a meeting click here: : http://valoremadvisors.com/remus

Remus®
Dedicated to Global Healthcare

Registered Office

1101 to 1103, South Tower, One 42,
B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli -Bopal Road, Ahmedabad,
Gujarat, India, 380054

CIN

L24232GJ2015PLC084536

ISIN

INE005T01011

NSE : REMUS

Thank You